PARNAX LAB LTD. - 506128 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5), we have received confirmation from our Registrar & Transfer Agents Link Intime India Pvt. Ltd., that there were no dematerialization requests received during the quarter ended 31st March, 2023, therefore we enclosed herewith the Confirmation Compliance Certificate for the quarter ended March 31, 2023. PARNAX LAB LTD. - 506128 - Closure of Trading Window
Pursuant to BSE Circulars dated 2nd April, 2019 vide Ref No: LIST/COMP/01/2019-20 please note that the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons with effect from Saturday, 1st April, 2023 for the purpose of consideration of Audited Financial Result for the Quarter and Year Ended ended March 31, 2023. The Trading Window shall open 48 hours after the Audited Financial Result for the Quarter and Year ended March 31, 2023, becomes generally available to the public. PARNAX LAB LTD. - 506128 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Pursuant to Regulation 8 (2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended by SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Board of Directors of the Company has revised the Company''s "Code for Fair Disclosure of Unpublished Price Sensitive Information", which is also available on the website of the Company i.e. www.naxparlab.com. PARNAX LAB LTD. - 506128 - Results-Un-Audited Financial Results For The Quarter Ended December 31, 2022.
Kindly find enclosed herewith a Copy of the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2022, along with the Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015. The aforesaid information and Financial Results are being made available on the Company''s website at www.naxparlab.com Kindly take on your record and acknowledge receipt of the same. PARNAX LAB LTD. - 506128 - Board Meeting Outcome for Board Meeting Of The Company To Consider And Approved The Standalone & Consolidated Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St Dec 2022, Along With The Limited Review Report Thereon.
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Tuesday, 14th February, 2023 at its Registered Office, the Board inter alia has transacted the following business: 1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended 31st December 2022, along with the Limited Review Report thereon. The Meeting commenced at 5.00 p.m. and concluded at 5.45 p.m. Kindly take the same on your record & Oblige. PARNAX LAB LTD. - 506128 - Board Meeting Intimation for Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended December 31, 2022.
PARNAX LAB LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve Standalone and Consolidated Un-audited IND- AS Compliant Financial Results along with the Limited Review Report for the quarter (Q3) and Nine Months ended 31st December, 2022, pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement, 2015. 2. Any other business with the permission of the chair and with the consent of a majority of the Directors present in the Meeting including at least one Independent Director. The approved results will be sent to you after the conclusion of the Board meeting. PARNAX LAB LTD. - 506128 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In reference to the above-captioned regulation, we have received confirmation from our Registrar & Transfer Agents Link Intime India Pvt. Ltd., that there were no dematerialization requests received during the quarter ended 31st December 2022, therefore we enclosed herewith the Confirmation Compliance Certificate for the quarter ended December 31, 2022. We request you to kindly take the same on your record. PARNAX LAB LTD. - 506128 - Closure of Trading Window
Pursuant to BSE Circulars dated 2nd April, 2019 vide Ref No: LIST/COMP/01/2019-20 please note that the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons with effect from Sunday, 1st January, 2023 for the purpose of consideration of Unaudited Financial Result for the Quarter and Nine Months ended December 31, 2022. The Trading Window shall open 48 hours after the Unaudited Financial Result for the Quarter and Nine Months ended December 31, 2022 becomes generally available to the public. The above is for your information and record. Kindly take the same on your record and oblige. PARNAX LAB LTD. - 506128 - Results-Un-Audited Financial Results For The Quarter Ended September 30, 2022.
Kindly find enclosed herewith the following: 1. A Copy of Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2022, along with the Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015. The aforesaid information and Financial Results are being made available on the Company''s website at www.naxparlab.com PARNAX LAB LTD. - 506128 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, 14th November, 2022 at its Registered Office, the Board inter alia has transacted the following business: 1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2022, along with the Limited Review Report thereon. The Meeting commenced at 5.00 p.m. and concluded at 5.45 p.m.